- Hansa Biopharma interim report January-March 2024
- Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
- Hansa Biopharma publishes 2023 Annual and Sustainability Reports
- Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer
- Hansa Biopharma Year-end report January-December 2023
More ▼
Key statistics
On Wednesday, Hansa Biopharma AB (HNSA:STO) closed at 27.88, 38.43% above the 52 week low of 20.14 set on Oct 16, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 27.96 |
---|---|
High | 27.96 |
Low | 27.20 |
Bid | 27.88 |
Offer | 27.88 |
Previous close | 27.96 |
Average volume | 238.28k |
---|---|
Shares outstanding | 52.67m |
Free float | 48.58m |
P/E (TTM) | -- |
Market cap | 1.47bn SEK |
EPS (TTM) | -16.07 SEK |
Data delayed at least 15 minutes, as of Apr 24 2024 17:00 BST.
More ▼